ABSTRACT
@#Idiopathic macular hole(IMH)refers to a full-thickness tissue defect of the retinal neuroepithelial layer in the macular region without obvious etiology. At present, with the gradual deepening of the understanding of IMH and the continuous innovation and improvement of its treatment methods, its treatment technology has also matured and diversified. Studies have shown that early IMH with small diameter can be observed and followed up. The Ocriplasmin has been approved for use in patients with small to medium sized macular holes and vitreomacular adhesion(VMA); internal limiting membrane(ILM)removal can improve anatomical closure rate. However, for IMH with a diameter of less than 250μm, it is uncertain whether ILM removal is always required. This paper discusses the pathogenesis, stages, classification and current treatment of IMH. Based on the characteristics of IMH and patient differences, an evidence-based medicine method is proposed to select the best and most practical treatment plan for individual patients.
ABSTRACT
Based on the indications, one‑third to one‑half of patients can achieve full‑thickness macular hole (FTMH) closure with or without the separation of vitreomacular adhesion (VMA) within 28 days of ocriplasmin treatment. The authors report the case of a 63‑year‑old man with early VMA separation and delayed FTMH closure after ocriplasmin treatment. Four weeks posttreatment, the posterior vitreous detachment occurred at the optic disk, and the macular hole (MH) started decreasing thereafter. MH closure was finally achieved at 10 weeks posttreatment, leaving minimal subretinal fluid. The patient’s vision improved from 0.8 LogMAR (pretreatment) to 0.3 LogMAR (12 weeks posttreatment). This case suggests that FTMH closure can be achieved within 28 days of ocriplasmin treatment.
ABSTRACT
Vitreous retinal interface abnormalities are associated with many macular diseases.The main approach of treatment is to release the vitreomacular adhesion with pars plana vitrectomy.Because of its complication and limitation,researches of pharmacologic posterior vitreous detachment (PVD) were undertaken.Gene recombinant ocriplasmin was proved by several experiments and clinical trials by inducing a complete PVD,showing its promising prospect.This article reviewed the literatures of ocriplasmin,including pathobiology in treatment of vitreomacular adhesion,pharmacokinetics,vitreodynamics,experimental studies and clinical trials and adverse events.